相似文献
1
Intratumoral Heterogeneity in Breast Cancer: A Comparison of Primary and Metastatic Breast Cancers.
Oncologist. 2017 Apr;22(4):487-490. doi: 10.1634/theoncologist.2016-0352. Epub 2017 Mar 24.
2
Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy.
Future Oncol. 2018 Apr;14(9):849-859. doi: 10.2217/fon-2017-0384. Epub 2018 Mar 12.
3
Hormone receptor, human epidermal growth factor receptor-2, and Ki-67 status in primary breast cancer and corresponding recurrences or synchronous axillary lymph node metastases.
Surg Today. 2020 Jul;50(7):657-663. doi: 10.1007/s00595-019-01831-8. Epub 2019 Jun 12.
4
Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Clin Cancer Res. 2005 May 1;11(9):3315-9. doi: 10.1158/1078-0432.CCR-04-1707.
5
Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
Breast Cancer Res. 2016 Jun 28;18(1):68. doi: 10.1186/s13058-016-0725-1.
6
Outcomes and recurrence patterns according to breast cancer subtypes in Korean women.
Breast Cancer Res Treat. 2015 May;151(1):183-90. doi: 10.1007/s10549-015-3390-7. Epub 2015 Apr 17.
7
Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer.
Int J Clin Exp Pathol. 2015 May 1;8(5):5744-8. eCollection 2015.
8
Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
Breast Cancer Res Treat. 2016 Feb;155(3):483-90. doi: 10.1007/s10549-016-3689-z. Epub 2016 Feb 4.
9
The Relationship of GATA3 and Ki-67 With Histopathological Prognostic Parameters, Locoregional Recurrence and Disease-free Survival in Invasive Ductal Carcinoma of the Breast.
Anticancer Res. 2020 Oct;40(10):5649-5657. doi: 10.21873/anticanres.14578.
10
Breast cancer metastasis to gynaecological organs: a clinico-pathological and molecular profiling study.
J Pathol Clin Res. 2019 Jan;5(1):25-39. doi: 10.1002/cjp2.118. Epub 2018 Oct 22.
引用本文的文献
1
Estrogen-Receptor-Low-Positive Breast Cancer: Pathological and Clinical Perspectives.
Curr Oncol. 2023 Nov 4;30(11):9734-9745. doi: 10.3390/curroncol30110706.
2
Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer.
J Transl Med. 2023 Jun 1;21(1):360. doi: 10.1186/s12967-023-04076-9.
3
Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance.
Front Oncol. 2023 Apr 28;13:1053125. doi: 10.3389/fonc.2023.1053125. eCollection 2023.
4
Using dynamic cell communication improves treatment strategies of breast cancer.
Cancer Cell Int. 2021 May 25;21(1):275. doi: 10.1186/s12935-021-01979-9.
5
Recurrence of Breast Carcinoma as Paget's Disease of the Skin along the Core Needle Biopsy Tract after Skin-Sparing Mastectomy.
J Breast Cancer. 2020 Apr;23(2):224-229. doi: 10.4048/jbc.2020.23.e16.
6
DENDRO: genetic heterogeneity profiling and subclone detection by single-cell RNA sequencing.
Genome Biol. 2020 Jan 14;21(1):10. doi: 10.1186/s13059-019-1922-x.
7
Celastrol mediates autophagy and apoptosis via the ROS/JNK and Akt/mTOR signaling pathways in glioma cells.
J Exp Clin Cancer Res. 2019 May 3;38(1):184. doi: 10.1186/s13046-019-1173-4.
8
Three-dimensional imaging and quantitative analysis in CLARITY processed breast cancer tissues.
Sci Rep. 2019 Apr 4;9(1):5624. doi: 10.1038/s41598-019-41957-w.
本文引用的文献
1
Genetic and phenotypic diversity in breast tumor metastases.
Cancer Res. 2014 Mar 1;74(5):1338-48. doi: 10.1158/0008-5472.CAN-13-2357-T. Epub 2014 Jan 21.
2
Intratumor heterogeneity: evolution through space and time.
Cancer Res. 2012 Oct 1;72(19):4875-82. doi: 10.1158/0008-5472.CAN-12-2217. Epub 2012 Sep 20.
3
Common protein biomarkers assessed by reverse phase protein arrays show considerable intratumoral heterogeneity in breast cancer tissues.
PLoS One. 2012;7(7):e40285. doi: 10.1371/journal.pone.0040285. Epub 2012 Jul 5.
4
Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
J Clin Oncol. 2012 Jul 20;30(21):2601-8. doi: 10.1200/JCO.2011.37.2482. Epub 2012 Jun 18.
5
Intra-tumour heterogeneity: a looking glass for cancer?
Nat Rev Cancer. 2012 Apr 19;12(5):323-34. doi: 10.1038/nrc3261.
6
Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance.
Mod Pathol. 2012 Jul;25(7):938-48. doi: 10.1038/modpathol.2012.36. Epub 2012 Mar 2.
7
Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients.
Cancer Sci. 2010 Sep;101(9):2074-9. doi: 10.1111/j.1349-7006.2010.01630.x.
8
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype.
J Clin Invest. 2010 Feb;120(2):636-44. doi: 10.1172/JCI40724. Epub 2010 Jan 25.
9
Genetic clonal diversity predicts progression to esophageal adenocarcinoma.
Nat Genet. 2006 Apr;38(4):468-73. doi: 10.1038/ng1768. Epub 2006 Mar 26.
Zotero 插件